A reecent study in the Jounral of Clinical Oncology examined the possibility of a new bispecific t-cell engager (BiTE) molecule for patients with muliple myeloma. Alex C. Minella, MD, one of the study's authors, sat down with MedPage Today to discuss the findings.
What are the highlights of the study?
Minella: In this first-in-human study, the anti-BCMA BiTE AMG 420 was given to 42 multiple myeloma patients with two or more prior lines. At the maximum tolerated dose of 400 µg per day, the response rate was 70% (seven of 10 patients), including five MRD-negative complete responses; all seven responders did so during the first cycle. In this study, 800 µg per day was considered not tolerable due to one instance each of grade 3 cytokine release syndrome and grade 3 polyneuropathy -- both resolved. Responses at the 400 µg per day dose lasted for at least a median of 9 months by the time of the data cutoff for the manuscript.
Read the full interview on MedPage Today.
Tags: bispecific t cell engagers, patient care, bite, medpage today